400 E Randolph St, Suite 705, Chicago, Illinois 60601, US
Founders & Team
Lewis Gruber, Misty Gruber
Number of employees
Total funding ($M)
Our initial focus is on gastrointestinal and related diseases that are eligible for FDA Fast-tracking.
SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells. Our current therapeutic focus is on certain rare and fast track diseases, including cancer metastasis and muscle wasting diseases, such as muscular dystrophy. Beyond these indications, senescent cells are causally implicated in a wide variety of diseases including: neurodegenerative diseases; autoimmune conditions, and infectious diseases. SIWA is currently optimizing its lead antibody, SIWA 318, and in parallel, seeking partnerships to advance SIWA 318 and other related technologies to broaden and accelerate its development pipeline.